Alimera Sciences Inc

Alimera Sciences — UBS Healthcare Conference (May 2015)

28 slides from Alimera Sciences's conference presentation, May 18, 2015

  1. Slide 1: UBS Healthcare Conference

    Slide 1: UBS Healthcare Conference

    UBS Healthcare Conference Dan Myers President and CEO

  2. Slide 2: Forward-Looking Statement

    Slide 2: Forward-Looking Statement

    2 Forward-Looking Statement • This presentation contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, regarding, among other things, the size of the global market opportunity for ILUVIEN, assumptions regarding the prevalence of diabetic ma

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    3 Investment Highlights  ILUVIEN is the only long-term, low dose sustained delivery corticosteroid approved for diabetic macular edema  ILUVIEN launched in the U.S. in Q1 2015 with national availability on February 23  ILUVIEN approved in 17 OUS countries with commercialization in the UK, Germany

  4. Slide 4: ILUVIEN Overview

    Slide 4: ILUVIEN Overview

    4 ILUVIEN Overview ILUVIEN Applicator ILUVIEN Implant • Non-bioerodible implant proven to last three years • Standard intravitreal injection with a 25- gauge needle • Addresses diabetic macular edema

  5. Slide 5: DME is A Significant Disease

    Slide 5: DME is A Significant Disease

    5 2015 2019 575,000 646,000 DME Prevalence / Incidence in the U.S. Existing DME Patients Incidence DME is A Significant Disease Source: Third party market research. (a) KANTAR market research. (b) 40+ age estimated for 2015 • 575,000 DME patients in the U.S. with vision threatening symptoms (a,b) •

  6. Slide 6: While There Are Competitors, ILUVIEN is Truly Unique

    Slide 6: While There Are Competitors, ILUVIEN is Truly Unique

    6 While There Are Competitors, ILUVIEN is Truly Unique Steroids Anti-VEGF Ozurdex Eylea Lucentis Avastin DME Approved     X (Used Off-Label) DME Approval Date Sept. 2014 June 2014 July 2014 Aug. 2012 N/A Therapy Duration Up to 36 Months ~3–5 Months ~2–3 Months Side Effects Cataract Formation, IO

  7. Slide 7: Diabetic Macular Edema Overview

    Slide 7: Diabetic Macular Edema Overview

    7 Diabetic Macular Edema Overview • Inflammatory disease associated with diabetes − Primary cause of vision loss in diabetic patients • Retinal swelling caused by leaky blood vessels in the macula • Blurring in middle of central visual field presents in early stage and typically leads to full vision

  8. Slide 8: DME Is Not Just a VEGF Disease

    Slide 8: DME Is Not Just a VEGF Disease

    8 Occludin Cytokines ICAM-1 VEGF Stromal-derived factor-1 Endothelin 1 PEDF PKC HIF-1α AGE & RAGE DAG Aldose reductase NOS x x x x DME x Affected by corticosteroids DME Is Not Just a VEGF Disease Biochemical Factors AGE, advanced glycation end products; DAG, diacylglycerol; HIF, hypoxia-inducible fa

  9. Slide 9: Anti VEGF treatments are standard of care but 50% of patients are refractory

    Slide 9: Anti VEGF treatments are standard of care but 50% of patients are refractory

    9 Anti VEGF treatments are standard of care but 40 – 50% of patients are refractory • US and European Pivotal trials for Lucentis® − ~40-50% of patients did not achieve 20/40 outcome(a) • DRCR.net(b) Protocol I − >50% of ranibizumab-treated eyes did not achieve a 2 or more line improvement in visual

  10. Slide 10: Alimera Market Research Confirms These Clinical Findings As Well

    Slide 10: Alimera Market Research Confirms These Clinical Findings As Well

    10 Alimera Market Research Confirms These Clinical Findings As Well Patients Achieving BCVA Levels Long Term (2 or More Years) BCVA 20/20, 15.0% BCVA 20/40, 31.6% BCVA 20/60 24.3% BCVA 20/80 16.4% BCVA 20/100 12.6% Source: ASI MR June 2014 ~55% of patients end up 20/60 or worse

  11. Slide 11: ILUVIEN's Role in the DME Treatment Paradigm: Current Therapy Allocation

    Slide 11: ILUVIEN's Role in the DME Treatment Paradigm: Current Therapy Allocation

    11 Physicians Have Identified ILUVIEN’s Role in the DME Treatment Paradigm Current Therapy Allocation Proprietary market research by SciMedica Group 37.9% 35.5% 1.9% 5.6% 1.2% 15.4% 2.0% 1.7% Avastin Lucentis Ozurdex Triamcinolone (IVTA) Eylea Laser Photocoagulation Vitrectomy Other

  12. Slide 12: ILUVIEN's Role in the DME Treatment Paradigm: Projected Therapy Allocation

    Slide 12: ILUVIEN's Role in the DME Treatment Paradigm: Projected Therapy Allocation

    12 Physicians Have Identified ILUVIEN’s Role in the DME Treatment Paradigm Projected Therapy Allocation with ILUVIEN Proprietary market research by SciMedica Group 30.3% 29.1% 2.3% 3.4% 2.5% 13.9% 1.7% 0.2% 16.6% Avastin Lucentis Ozurdex Triamcinolone (IVTA) Eylea Laser Photocoagulation Vitrectomy O

  13. Slide 13: ILUVIEN Efficacy

    Slide 13: ILUVIEN Efficacy

    13 ILUVIEN Efficacy Months IL U V IE N Pat ie n ts W it h I m p ro v eme n t in B C V A F ro m B asel in e 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 0 3 6 9 12 15 18 21 24 27 30 33 36 ≥ 1 Letter ≥ 1 Line ≥ 2 Line ≥ 3 Line

  14. Slide 14: No Unexpected Side Effects

    Slide 14: No Unexpected Side Effects

    14 No Unexpected Side Effects (a) Ophthalmology, Epub, 2014 and Campochiaro PA, et al. Ophthalmology. 2012;119:2125-2132. ILUVIEN® Ozurdex® Cataract Surgery(a) 80.0% 59.2% % on IOP Medication(a) 38.2% 41.5% IOP Surgery(a) 4.8% 0.6% IOP experience is expected to be lower based on the FDA label – No I

  15. Slide 15: A Significant % of the Population Tolerates Corticosteroids

    Slide 15: A Significant % of the Population Tolerates Corticosteroids

    15 A Significant % of the Population Tolerates Corticosteroids Kantar Health Epidemiology Review Study 2011 (a) Estimate based on average % of patients not requiring IOP medication • Majority of patients receiving an intravitreal corticosteroid do not require IOP lowering medication − FAME Study – 6

  16. Slide 16: Look Forward. Commercialization Update

    Slide 16: Look Forward. Commercialization Update

    LOOK FORWARD. Commercialization Update

  17. Slide 17: Global Commercialization Status

    Slide 17: Global Commercialization Status

    17 Global Commercialization Status France Spain Portugal Italy Ireland U.K. Germany Poland Belgium Denmark Netherlands Austria Marketed Approved U.S. CR

  18. Slide 18: Global Commercial Sales

    Slide 18: Global Commercial Sales

    18 Global Commercial Sales Q3 2013 Q4 2013 Q1 2014 Q2 2014 Q3 2014 Q4 2014 Q1 2015 $758,000 $935,000 $2,100,000 $2,201,000 $2,408,000 $1,741,000 $3,938,000 European Net Pricing Ranges from $5,500 to $9,600

  19. Slide 19: Payer Coverage is Extremely Positive

    Slide 19: Payer Coverage is Extremely Positive

    19 Payer Coverage is Extremely Positive 49.2 131.1 - 13.9 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Medicare Top 25 Commercial Millions of Lives Covered In Process Covered per FDA Label

  20. Slide 20: Usage is Significant and Growing

    Slide 20: Usage is Significant and Growing

    20 Usage is Significant and Growing 45 86 127 171 0 20 40 60 80 100 120 140 160 180 4 week ending Feb 13 4 week ending Mar 13 4 week ending Apr 10 4 week ending May 8 Completed Benefits Investigations (Rolling 4 week)

  21. Slide 21: Adjudication is the challenge, coverage is not

    Slide 21: Adjudication is the challenge, coverage is not

    21 Adjudication is the challenge, coverage is not • No specific J-code in 2015 • But − We are providing significant support to the practices − Over 700 physicians have signed up for the support − 98% of Benefit Investigations to date indicate patient coverage − Claims are getting paid • Team of fiel

  22. Slide 22: Strong Economics in the U.S.

    Slide 22: Strong Economics in the U.S.

    22 Ozurdex Eylea Lucentis Avastin Annual Labeled Injections Every 3 years 3 – 4 4 – 6 4 – 6 ~4 – 6 Cost of Injection $8,800 $1,300 $1,850 $1,170 $50 1st Year Cost(a) $8,800 $3,250 $9,250 $5,850 $250 3-Year Cost(a) $8,800 $9,750 $27,750 $17,550 $750 Strong Economics in the U.S. Competitive Landscape

  23. Slide 23: European Commercial Infrastructure

    Slide 23: European Commercial Infrastructure

    23 European Commercial Infrastructure • Philip Ashman is the SVP and Managing Director in Europe with 24 years of experience • EU Medical and Sales Operations functions • Arvato Healthcare for third party logistics European Office Germany United Kingdom Portugal France Country Manager Brand Manager

  24. Slide 24: ILUVIEN Intellectual Property Overview

    Slide 24: ILUVIEN Intellectual Property Overview

    24 Issued 6,217,895, 6,548,078 & 8,252,307 Release front v. back ILUVIEN Intellectual Property Overview Data Exclusivity Marketing Exclusivity New Indication Issued European EP1276462 Issued EP Patent with Claims to Injectable Device 10156691.7 Pending EP Reduced IOP Application (if issued) 10840065

  25. Slide 25: Financial Position

    Slide 25: Financial Position

    25 Financial Position • March 31, 2015 cash balance of $61.3 million • Q1 2015 cash flow used in operations of $14.7 million included – − $2.7 million increase in accounts receivable associated with the extended terms provided to U.S. physicians − $2 million milestone payment related to the FDA appr

  26. Slide 26: Investment Highlights

    Slide 26: Investment Highlights

    26 Investment Highlights  ILUVIEN is the only long-term, low dose sustained delivery corticosteroid approved for diabetic macular edema  ILUVIEN launched in the U.S. in Q1 2015 with national availability on February 23  ILUVIEN approved in 17 OUS countries with commercialization in the UK, German

  27. Slide 27: UBS Healthcare Conference

    Slide 27: UBS Healthcare Conference

    UBS Healthcare Conference Dan Myers, Alimera President and CEO

  28. Slide 28: Experienced Leadership: 100+ Years in Ophthalmology

    Slide 28: Experienced Leadership: 100+ Years in Ophthalmology

    28 Experienced Leadership: 100+ Years in Ophthalmology C. Daniel Myers Co-Founder, President, CEO and Director • 30 years in ophthalmology • Novartis Ophthalmics (formerly CIBA Vision): Founding member, VP Sales & Marketing (1991-1997), President (1997-2003), J&J, Allergan Richard S. Eiswirth, Jr. C

Source: SEC EDGAR · 8-K filed May 18, 2015

More decks from Alimera Sciences Inc